Armistice Capital, LLC Increases Stake in Kyntra Bio, Inc. to 9.88%

On May 15, 2026, Armistice Capital, LLC and Steven Boyd filed a Schedule 13G/A disclosing an increased ownership position in Kyntra Bio, Inc. (formerly FibroGen, Inc.). The filing reveals that the reporting persons beneficially own 400,000 shares of common stock, representing a 9.88% stake in the company. This marks a significant increase from a previously reported 0% position as of the event date on March 31, 2026. Armistice Capital, LLC serves as the investment manager for Armistice Capital Master Fund Ltd., which directly holds the shares. Steven Boyd, as the managing member of Armistice Capital, LLC, shares voting and dispositive power over these securities. The filing was made under Rule 13d-1(b), indicating that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The Master Fund retains the right to receive dividends and proceeds from the sale of the reported securities.